Solid state forms of pirtobrutinib and process for the preparation of intermediate thereof

Abstract

Aspects of the present application relates to solid state forms of Pirtobrutinib such as novel crystalline form P1, amorphous solid dispersions comprising Pirtobrutinib and pharmaceutically acceptable carriers and processes thereof, wherein the pharmaceutically acceptable carrier is selected from the group consisting of HPMC phthalate, HPC, Eudragit L 100, microcrystalline cellulose, carboxymethyl cellulose, mannitol, Neusilin, cellulose acetate phthalate, polyvinyl alcohol, polylactic-co-glycolic acid, polyvinyl acetate phthalate, sodium alginate, beta cyclodextrin, and mixtures thereof. Aspects of the present application relates to process for the preparation of [(1S)-2,2,2-trifluoro-1-methyl-ethyl]hydrazine or its salts.

Dependencies are inferred from the claim text.